| Entry |
|
| Name |
Ranitidine (USAN/INN);
Ranitidine (TN)
|
| Formula |
C13H22N4O3S
|
| Exact mass |
314.1413
|
| Mol weight |
314.4038
|
| Structure |

     |
| Activity |
Antagonist [to histamine H2 receptors]
|
| Remark |
|
| Target |
|
| Pathway |
|
| Metabolism |
Transporter: SLC22A2 [HSA: 6582]
|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565], CYP3A [KO: K07424]
Transporter inhibition: SLC22A2 [HSA: 6582]
 |
| Pathway map |
|
| Structure map |
| Antiulcer drugs | | Histamine H2/H3 receptor agonists/antagonists |
|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BA H2-receptor antagonists
A02BA02 Ranitidine
D00422 Ranitidine (USAN/INN)
USP drug classification [BR:br08302]
Gastrointestinal Agents
Histamine2 (H2) receptor Antagonists
Ranitidine
D00422 Ranitidine (USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
H2-receptor [HSA:3274] [KO:K04150]
Ranitidine [ATC:A02BA02]
D00422 Ranitidine (USAN/INN)
 |
| Other DBs |
CAS: 66357-35-5 PubChem: DrugBank: LigandBox: NIKKAJI: |
| KCF data |
 ATOM 21
1 C8y C 19.0765 -23.1392
2 O2x O 20.1949 -23.9781
3 C8x C 19.4959 -21.8111
4 C1b C 17.8182 -23.8382
5 C8y C 21.3133 -23.1392
6 C8x C 20.8939 -21.8111
7 N1c N 16.6298 -23.1392
8 C1b C 22.5017 -23.8382
9 C1a C 15.4415 -23.8382
10 C1a C 16.6298 -21.7412
11 S2a S 23.6900 -23.1392
12 C1b C 24.9482 -23.8382
13 C1b C 26.1366 -23.1392
14 N1b N 27.3249 -23.8382
15 C2c C 28.5831 -23.1392
16 C2b C 29.7715 -23.8382
17 N1b N 28.5831 -21.7412
18 N2b N 30.9599 -23.1392 #+
19 C1a C 27.3249 -21.0422
20 O3a O 30.9599 -21.7412 #-
21 O3a O 32.2181 -23.8382
BOND 21
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 3 6 1
6 4 7 1
7 5 8 1
8 7 9 1
9 7 10 1
10 8 11 1
11 11 12 1
12 12 13 1
13 13 14 1
14 14 15 1
15 15 16 2
16 15 17 1
17 16 18 1
18 17 19 1
19 18 20 1
20 18 21 2
21 5 6 2
|